41
Psychotropic Medications and Their Use with Children A Web-based Educational Program for Children’s Medical Services Care Coordination Daniel Armstrong, Ph.D. Mailman Center for Child Development Batchelor Children’s Research Institute Department of Pediatrics University of Miami School of Medicine

Daniel Armstrong, Ph.D. Mailman Center for Child Development

  • Upload
    nieve

  • View
    34

  • Download
    0

Embed Size (px)

DESCRIPTION

Psychotropic Medications and Their Use with Children A Web-based Educational Program for Children’s Medical Services Care Coordination. Daniel Armstrong, Ph.D. Mailman Center for Child Development Batchelor Children’s Research Institute Department of Pediatrics - PowerPoint PPT Presentation

Citation preview

Page 1: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications and Their Use with Children

A Web-based Educational Program for Children’s Medical Services Care

Coordination

Daniel Armstrong, Ph.D.Mailman Center for Child DevelopmentBatchelor Children’s Research Institute

Department of PediatricsUniversity of Miami School of Medicine

Page 2: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications for Children: What are the Issues?

• Lack of access to child mental health services• Inadequate numbers of mental health

practitioners with training and experience with children

• Underserved populations (Location, Culture)• Poor/non-existent empirical data on safety or

efficacy of most psychotropic medications with children

Page 3: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications for Children: What are the Issues?

• Inadequate attention to risks associated with selected sub-groups of children

• Absence of guidelines for prescribing, monitoring

• Role of the pediatrician in addressing these problems: AAP (2001): The new morbidity revisited.

Page 4: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Lack of Access to Mental Health Services

• Estimated 13 million children in the U.S. have diagnosable mental, emotional, or behavioral disorders

• Two thirds have no mental/behavioral health treatment

Page 5: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Lack of Access to Mental Health Services

• These numbers do not include:–Children under 4–Children with primary medical problems

where behavioral problems are secondary (e.g. cancer, HIV)–Children with behavioral problems that do

not meet disorder diagnostic criteria

Page 6: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Children’s Access to Mental and Behavioral Health Services

Types of Problems

• Serious Mental Illness• Developmental Disorders• Problems associated with environmental risk– Maternal risk factors: Depression, social isolation– Exposure to violence – Poverty and homelessness

• Physical or Chronic Illness

Page 7: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Inadequate Number of Child Mental Health Providers

• Estimates:– Child & Adolescent Psychiatrists: 6,000– Child Clinical/Pediatric Psychologists: 3,000– School Psychologists: 3,000– Developmental and Behavioral Pediatricians:

<1000– Clinical Social Work, Psychiatric Nurse Specialists:

2,000• Total: 15,000 or 1/866 children in need

Page 8: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Underserved Populations

• Lack of access to mental health services is highest among children of:– Poverty– Non-majority culture– Rural communities

• Underserved populations rarely have access to child mental health professional with cultural competence

Page 9: Daniel Armstrong, Ph.D. Mailman Center for Child Development

What are “psychotropic” medications?

• Medications administered for the purpose of maintaining or improving behavior, emotions, mood, or thinking

• Other medications may have effects on behavior, emotions, mood, or thinking, but are not prescribed for that purpose

Page 10: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Psycho-Stimulants– Most often used in treatment of Attention Deficit

Hyperactivity Disorder– Also used in treatment of behavior disabilities in

children with autism and other developmental disabilities

– May have some benefits to children with long-term, late consequences of chronic illnesses (e.g., brain tumors, leukemia, stroke, neurotrauma)

Page 11: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Stimulants (Schedule II Medications)– Methylphenidate • Commercial names: Ritalin, Concerta, Focalin,

Methylin, Metadate - methylphenidate in various forms of admistration

– Amphetamine & dextroamphetamine• Commercial names: Adderall, Dexedrine

– Pemoline• Commercial Name: Cylert

Page 12: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Stimulants•Most Common Side Effects–Nervousness & Jitteriness–Insomnia–Decreased Appetite & Weight Loss–Headaches or Stomachaches–Skin Rash–Social Withdrawal

Page 13: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Stimulants• Rare adverse events–Tachycardia, changes in blood pressure,

nausea, dizziness, and palpitations• Overdose symptoms–Vomiting, agitation, tremors, muscle

twitching, convulsions, hallucinations, delirium, sweating, and cardiac arrhythmias–Contact Poison Control Center

Page 14: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Non-Stimulants (Not Schedule II)– Atomoxetine (norepinephrine reuptake inhibitor)

• Commercial Name: Strattera– Common Side Effects

• Excessive tiredness, insomnia• Increase in heart rate & blood pressure• Sexual side effects• Enlarged Pupils• Weight fluctuations• Headache, dizziness• Nausea, vomiting, stomach pain• Mood swings and irritability

Page 15: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• There is a lot of controversy about the use of stimulants with children– Recent AAP, AACAP reviews provide evidence of

benefits for children with significant behavior problems/ADHD

– Some children do experience side effects, some significant

– Stimulants are the most studied medications used with children, so safety and efficacy information is available

Page 16: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Anti-depressants– Used in the treatment of• Depression• Anxiety/Panic Disorders• Obsessive-Compulsive Disorder (OCD)

– One class of anti-depressants (SSRIs) are under FDA black-box warning because of increased suicide risk

Page 17: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Anti-Depressants– Selective Serotonin Reuptake Inhibitors (SSRIs)• Fluoxetine (Commercial Name: Prozac)-only drug currently

approved for use in children by FDA)• Paroxetine (Commercial Name: Paxil)• Sertraline (Commercial Name: Zoloft)• Citalopram (Commercial Name: Celexa)• Fluvoxamine Maleate (Commercial Name: Luvox)-approved

for with Obsessive Compulsive Disorder• Clomipramine (Commercial Name: Anafranil) approved for

use with OCD

Page 18: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Side Effects of SSRIs– Common• Anxiety & nervousness• Insomnia• Mania and agitation• Decreased appetite• Rash or hives

– Rare but significant Events• Thoughts of suicide, attempted suicide• Seizure

Page 19: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Other non-SSRI anti-depressants–Buproprion (Commercial Names: Wellbutrin,

Zyban)• Side effects: Agitation, anxiety, insomnia,

hypertension, possible hallucinations, weight loss, dose related risk of seizure

–Propranolol (Commercial Name: Inderal)• Side effects: Dizziness, insomnia, tiredness,

stomach pain, vomiting, diarrhea; difficulty breathing, sore throat, unusual bleeding, swelling of feet or hands, slow heartbeat, chest pain)

Page 20: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

–Other non-SSRI anti-depressants • Venlafaxine (Commercial Name: Effexor)–Side effects: Dizziness, drowsiness, sleep

problems, difficulty breathing, cold hands or feet, hallucinations, irregular heartbeat, hypertension; In rare cases, fever or increased depression.

Page 21: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Atypical Anti-psychotics– Used in treatment of childhood schizophrenia,

bipolar disorder – Beginning to be used in treatment of children with

developmental disabilities, particularly autism

Page 22: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Atypical Anti-psychotics– Risperidone (Commercial Name: Risperdal)– Clozapine (Commercial Name: Clozaril)– Olanzapine (Commercial Name: Zyprexa)– Quetiapine (Commercial Name: Seroquel)

– White blood cells checked weekly

Page 23: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Psychotropic Medications Used with Children

• Atypical Anti-psychotics– Common Side Effects• Hyperglycemia• Diabetes Mellitus• Hypotension• Cognitive and Motor Impairments

– Rare Side Effects• Serious cardiac abnormalities• Serious neuromuscular effects

Page 24: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Current Prescription Patterns

• Approximately 80% of psychotropic medications are prescribed by primary care physicians (internal medicine, family medicine, & pediatrics)

• Primary pediatric patterns– Overwhelmingly stimulant medications– Some anti-depressants, anxiolytics

Page 25: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Concerns

• Empirical support for use with children– Extensive literature supporting use of

stimulants for ADHD • Primarily dexedrine & methylphenidate• Limited literature on newer stimulants

(long-lasting, methylphenidate/dexedrine combinations, methylphenidate patch, etc.)

Page 26: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Concerns

–Despite increasing use trends, and availability of new “atypical” psychotropic medications, almost no empirical support for use of other psychotropics with children, particularly those under age 6• Efficacy• Safety

Page 27: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Concerns• FDA Black Box Warnings (2004)-SSRIs– Elevated risk for suicide in children• At start of medication trial, at discontinuation• Specific concerns for adolescents

– Risk/Benefit Balance• In randomized, double-blind, placebo-

controlled clinical trials, SSRIs did not offer a significant benefit over placebo

Page 28: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Concerns

• Some concerns raised recently about several stimulants: long QT syndrome, etc.– Cardiovascular monitoring recommended for

children on a number of psychotropic medications

Page 29: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Concerns

• External Pressure to Prescribe– Parents– Schools & Agencies– Insurance Providers

• External Pressure to Not Prescribe– Parents– Advocacy Groups

Page 30: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Things to Consider Before Prescribing

• Training & experience (Competence)?• Collaborative relationship with mental

health specialist?

Page 31: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Other Things to Consider

• Is the diagnosis accurate?• What treatments are available for this problem?• What is the relative effectiveness of each?• Are combinations of approaches most

appropriate?

Page 32: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Other Things to Consider

– Empirical support for psychotropics– Empirical support for behavioral interventions • Recent publications on empirically supported

treatments:, Society of Clinical Child Psychology, Society of Pediatric Psychology

– Empirical support for combined approaches• AAP (2001) Statement on ADHD

Page 33: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Other Things to Consider

• What resources are available to the family?• What are the risks of using a psychotropic

medication compared with the risks of not using it?

Page 34: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Other Things to Consider

• What educational information is available for parents, teachers about the medication?

• What consent process is used?– Understanding of risks and benefits– Understanding of monitoring plan, as well as plan

for adjusting or discontinuing meds or other concurrent treatments

Page 35: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Other Things to Consider

• Special Considerations– Use of multiple psychotropic medications– Use of psychotropics with other medications (e.g.,

in chronic illness)– Medication and dose sensitivity in children with CNS

disease, treatment• Increased toxicity• Interference with other drug mechanisms

Page 36: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Suggestions for Use of Psychotropics with Children

• Establish plan for monitoring effectiveness • Obtain accurate medication history– Current medications (including OTCs)– Previous medications

• Establish plan for monitoring adherence• Establish plan for monitoring drug toxicity

Page 37: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Pitfalls to Avoid

• Avoid pressure to prescribe when inappropriate, or to not prescribe when appropriate

• Avoid pressure to use psychotropics to the exclusion of other effective and available interventions

Page 38: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Pitfalls to Avoid

• Avoid non-standard dosing, dose-escalation, or poly-pharmacy approaches without consultation

• Avoid practicing outside competence, experience, or comfort

Page 39: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Other Roles for Pediatric Care Providers

• Serve as a source of information about psychotropic medications for parents, schools, and communities

• Identify IRB approved clinical trials and make participation available to parents

• Advocate at community, state, and national level for increased access to child-competent mental health services

Page 40: Daniel Armstrong, Ph.D. Mailman Center for Child Development

Acknowledgements

• This session is part of an ongoing training collaboration between the Florida Department of Health, Children’s Medical Services, and the Mailman Center for Child Development at the University of Miami Miller School of Medicine.

Page 41: Daniel Armstrong, Ph.D. Mailman Center for Child Development

References and Resources

• NIMH. Treatment of Children with Mental Disorders. http://www.nimh.nih.gov/publicat/childqa.cfm

• Florida Department of Children and Families. 2005. Ensuring informed and appropriate use of psychotropic medications with children in department custody. http://www.dcf.state.fl.us/mentalhealth/psychpres0111.ppt#407,2,Ensuring Appropriate and Informed Use of Psychotropic Medications With Children in Department Custody

• The Center for Health and Health Care in the Schools. 2004. Psychotropic drugs and children: Use, trends, and implications for school. http://www.healthinschools.org/press/psych.asp